Clinical Trials

MSK scientists are at the forefront of epigenetic drug discovery, with four new compounds in early-stage clinical investigation. The following phase I trials are investigating the safety and potential effectiveness of these drugs in leukemias and other blood disorders:

  • A Phase I Study of AG-221 in Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH2 Mutation
  • A Phase I Study of Oral AG-120 to Treat Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH1 Mutation
  • A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
  • A Phase I Study of EPZ-5676 to Treat Children with Recurrent or Persistent MLL-Mutant Acute Leukemia
  • A Phase I Study of CPI-0610 in Patients with Acute Leukemia, Myelodysplastic Syndromes, or Myelodysplastic/Myeloproliferative Neoplasms